Cellular Biomedicine Group Acquires CAR-T Technology From China Hospital

February 9, 2015 -- Cellular Biomedicine Group, a China-US cell therapy company, acquired CAR-T cancer immunotherapy technology from the Chinese PLA General Hospital of Beijing. The two groups will form a partnership for further development of the products in China. The PLA Hospital has already conducted early clinical trials of the technology on CD19-positive acute lymphoblastic leukemia, CD20-positive lymphoma, CD30-positive Hodgkin's lymphoma and EGFR-HER1-positive advanced lung cancer. The data from the Phase I and II trials is included in the deal.

Help employers find you! Check out all the jobs and post your resume.

Back to news